Skip to search formSkip to main contentSkip to account menu

VX-970

Known as: ATR Kinase Inhibitor VX-970 
An inhibitor of ataxia telangiectasia and rad3-related (ATR) kinase, a DNA damage response kinase, with potential antineoplastic activity. ATR kinase… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

IsoxazolesPyrazines
NCIt Antineoplastic Agent Terminology

Narrower (1)

VE-822

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Randomized phase II trial of topotecan plus M6620 (VX-970) versus topotecan alone in patients with relapsed small-cell neuroendocrine cancers including small cell lung cancer.
TPS3653Background: Ataxia telangiectasia and Rad3-related (ATR) is an essential kinase that senses stressed replication forks and… 
2018
2018
Dose expansion cohort of a phase I trial of M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC…
e21048Background: Ataxia telangiectasia and Rad3-related protein (ATR) is an essential regulator of the DNA damage response and… 
2018
2018
Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC).
2017
2017
Phase I trial of the triplet veliparib + VX-970 + cisplatin in patients with advanced solid tumors.
TPS2609Background: The DNA damage response (DDR) pathway is a key element of cellular integrity. Platinum compounds form covalent… 
2017
2017
Abstract 1187: Synthetic lethality screening reveals ATR as responsible for oxaliplatin resistance in colorectal cancer cells
Despite the recent advances achieved in the treatment of colon cancer, tumor resistance is a frequent cause of chemotherapy… 
2017
2017
Les thérapies ciblées de la réponse aux dommages de l’ADN dans le traitement du cancer : l’exemple du VX-970
1. Les therapies ciblees (TC) representent une avancee therapeutique revolutionnaire dans la prise en charge du cancer. Elles… 
2016
2016
Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies.
2504Background: ATR is a regulator of cellular responses to replication stress, where it signals DNA damage repair by homologous… 
2016
2016
Abstract CT012: Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792)
Background: ATR is a regulator of the cellular response to replication stress, where it signals DNA damage repair through the… 
2015
2015
Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer…
Background: ATR mediates the homologous recombination DNA repair pathway and cellular response to replication stress. VX-970 is a… 
2015
2015
Abstract 1644: VX-970, the first-in-class inhibitor of the DNA damage repair enzyme ATR
Proficient repair of DNA damage is important for cancer cell survival and is a leading cause for the poor response many patients… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)